Solosa

Quick links to important sections

Solosa

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Solosa

What is Solosa?

Solosa is a medication belonging to the class of drugs known as sulfonylureas. It is used as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Mechanism of Action

The primary mechanism of Solosa involves stimulating the release of insulin from functioning pancreatic beta cells. It works by binding to specific receptors on the surface of these cells, which leads to the closure of potassium channels and the opening of calcium channels. This process triggers the secretion of insulin into the bloodstream, helping to lower blood glucose levels.

Therapeutic Use

Solosa is prescribed for individuals whose blood sugar levels cannot be adequately controlled by lifestyle modifications alone. In type 2 diabetes, the body either does not produce enough insulin or cannot effectively use the insulin it produces. By enhancing the natural production of insulin, Solosa helps maintain glucose levels within a target range.

In some cases, Solosa may be used in combination with other glucose-lowering medications, such as metformin, or alongside insulin therapy when a single agent does not provide sufficient glycemic control. Its use is specific to type 2 diabetes and is not intended for the treatment of type 1 diabetes or diabetic ketoacidosis.

What side effects are possible with Solosa?

Solosa: Possible Side Effects and Safety Information

Solosa (Glimepiride) is associated with officially documented adverse reactions that are classified by frequency and grouped by the body system affected. All safety information is based strictly on regulatory documents, such as the FDA Prescribing Information and the Summary of Product Characteristics (SmPC).

Frequency and Systemic Adverse Reactions

The primary and most common (ge 5%) adverse reaction is Hypoglycemia (low blood sugar), which is inherent to the drug's mechanism as an insulin secretagogue. Other common effects include Headache, Nausea, and Dizziness. Less frequent effects are classified by the organ system involved:

  • Blood and Lymphatic System: Rare effects include Leukopenia, Agranulocytosis, and Hemolytic Anemia, which are often reversible upon cessation.
  • Hepatobiliary Disorders: Rare cases of impaired liver function, such as Hepatitis, Jaundice, and Liver Failure, have been reported.
  • Skin and Immune System: Allergic reactions (e.g., pruritus, rash) occur. Serious hypersensitivity reactions, including Anaphylaxis, Angioedema, and Stevens-Johnson Syndrome, are documented in postmarketing reports (Frequency Not Known).

Serious Safety Considerations and Restrictions

Severe hypoglycemia may lead to unconsciousness, convulsions, or permanent impairment of brain function. The class of sulfonylurea drugs, to which Glimepiride belongs, has been associated with a potential for increased cardiovascular mortality.

Safety constraints and population-specific notes are officially stated:

  • Contraindications: Solosa is not to be used in cases of Type 1 Diabetes, Diabetic Ketoacidosis, or severe renal or hepatic function disorders.
  • G6PD Deficiency: Due to the risk of hemolytic anemia, caution is advised in patients with G6PD deficiency, and a non-sulfonylurea alternative should be considered.
  • Elderly Patients: This population may be particularly susceptible to hypoglycemia, and early warning symptoms of low blood sugar may be less pronounced. The risk of hypoglycemia is also documented to be increased in the initial weeks of treatment.

The official safety profile structures the understanding of risks by emphasizing the high frequency of hypoglycemia, while maintaining documentation on rare, serious hematologic and hepatic risks, and defining clear restrictions based on patient's underlying conditions and general health status.

Overdose and Emergency Response

Overdose Scope

The fundamental risk following an overdose of Solosa (Glimepiride) is hypoglycemia (low blood sugar), which can range from mild symptoms to life-threatening complications, as documented in regulatory prescribing information.

Component Official Regulatory Statement
Documented overdose presentations Overdose causes hypoglycemia, marked by neurological disturbances (e.g., confusion, headache, impaired alertness, visual and speech disorders, tremor) and systemic signs (e.g., lassitude, sweating, anxiety, tachycardia, palpitations).
Physiological systems affected The Central Nervous System and Cardiovascular System are affected. Severe hypoglycemia can lead to seizures, coma, permanent impairment of brain function, and in rare cases, death.
Dose-related or exposure-related factors The long duration of Glimepiride's action means that hypoglycemia may be prolonged or recur even after initial correction.
Population-specific overdose notes The risk of severe outcomes is officially noted as higher in the elderly, the malnourished, and patients with severe hepatic or renal impairment.
Emergency-response statements Immediate medical treatment must be sought for any suspected overdose. For severe presentations (e.g., collapse, seizure, or inability to awaken the victim), emergency services must be contacted immediately.

Official Overdose Statements

  • Immediate medical treatment is required for all suspected overdoses involving Glimepiride.
  • Management involves the prompt administration of carbohydrates and, for severe cases, Intravenous Dextrose.
  • Patients must remain under close observation by a physician due to the documented risk of rebound hypoglycemia.

The regulatory profile strictly defines the overdose state based on hypoglycemia and the risk of severe neurological sequelae. It mandates specific, structured emergency action, including hospitalization or prolonged monitoring, to manage the protracted and recurrent nature of the drug's effect.

Therapeutic Uses of Solosa

What Solosa Treats: Main Uses and Benefits

Solosa (Glimepiride) is generally used to address the core metabolic condition of Type 2 Diabetes Mellitus in adults when high blood sugar cannot be controlled adequately through diet and exercise alone. It is applied across chronic clinical settings, particularly relevant when symptoms associated with glucose dysregulation require consistent, supportive pharmacological management.

The medication’s primary role is to manage the symptom patterns of persistent hyperglycemia, which include elevated Fasting Plasma Glucose (FPG) and high Postprandial Glucose (PPG). The therapeutic benefit is to help lower blood glucose levels and contribute to the reduction of Elevated Glycosylated Hemoglobin (HbA1c), which supports long-term metabolic stability. It is commonly used to help with managing T2DM, addressing symptoms related to high blood sugar, and supporting overall glycemic control.

“Supporting better overall control may assist with easing the overall symptomatic burden and supports general well-being during symptomatic phases.”

Solosa is commonly used in situations where chronic elevation of blood sugar is considered to affect functional stability for the patient. By supporting better overall control, the medication may assist with maintaining functional stability for patients with the chronic condition.


Quick Fact: Relief for Persistent Hyperglycemia The medication is relevant for managing the symptomatic domain of chronic high blood sugar when lifestyle interventions are considered appropriate but require additional symptomatic support.


Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Solosa (Glimepiride)

Solosa (Glimepiride) is officially indicated for use only in adults with Type 2 Diabetes Mellitus to improve glycemic control. Eligibility to use the medicine is strictly defined by regulatory authorities and includes several absolute exclusions and restrictions.


Absolute Contraindications (Must Not Use)

The medicine is contraindicated in several populations, meaning use is prohibited:

  • Patients with known hypersensitivity to Glimepiride, other sulfonylureas, or sulfonamide derivatives (sulfa drugs).
  • Patients with Type 1 Diabetes Mellitus or Diabetic Ketoacidosis (DKA).
  • Women who are pregnant.
  • Patients with severe renal function disorders or severe hepatic function disorders.

Population Restrictions

Population Group Regulatory Status
Pediatric Patients (< 18 yrs) Not recommended; safety and effectiveness not established
Lactating Women Not recommended (during breastfeeding)
Older Adults Caution is advised due to increased risk of hypoglycemia and age-related organ decline

Use is restricted in patients with impaired hepatic or renal function, requiring special consideration. Patients with a known G6PD deficiency should also use caution, and a non-sulfonylurea alternative may be considered.

What should I know about interactions with other medicines?

The interaction profile for Solosa (Glimepiride) is officially documented by regulatory authorities, focusing on how co-administered substances affect drug exposure or glucose control. Interactions are primarily classified by their effect on either pharmacokinetics or pharmacodynamics.

Pharmacokinetic Interactions

The exposure of Glimepiride is modified by substances that interact with its metabolic clearance or absorption. Co-administration with CYP2C9 inhibitors may increase Glimepiride plasma concentrations, while CYP2C9 inducers may decrease exposure. A critical absorption-based interaction exists with Colesevelam, which reduces Glimepiride uptake; to mitigate this effect, Glimepiride must be administered at least 4 hours prior to Colesevelam.

Pharmacodynamic and Consumption Interactions

A pharmacodynamic reinforcement of glucose lowering occurs when Solosa is used with other anti-diabetic agents, leading to a significantly increased risk of hypoglycemia. This effect can be potentiated by other drug classes, such as NSAIDs and Beta-blockers, while agents like Diuretics or Corticosteroids may attenuate it. Furthermore, excessive consumption of alcohol is associated with altered glycemic control and an increased risk of severe hypoglycemia. This hypoglycemic risk is noted to be heightened in specific populations, including the elderly and patients with underlying hepatic or renal impairment.

Mechanism of Action

Targeting the KATP Channel for Insulin Secretion

The central mechanism involves the blockade of the ATP-sensitive Potassium Channel ( KATP channel) on the pancreatic beta-cell membrane by binding to its SUR1 subunit. This binding initiates a cascade of cellular events—membrane depolarization and rapid calcium ion influx—that leads to the exocytosis (release) of stored endogenous insulin into the bloodstream.

Modulation of Peripheral Glucose Uptake

Beyond its action on the pancreas, Glimepiride also exerts extrapancreatic effects that modulate glucose homeostasis. It supports the increased movement and activity of Glucose Transporter type 4 ( GLUT-4) on the surface of peripheral muscle and fat cells. This mechanism leads to the potentiation of tissue sensitivity to insulin, resulting in the enhanced clearance of circulating glucose from the blood.

Mechanistic Constraint: beta-Cell Function Dependence

This drug operates as an insulin secretagogue, meaning its core function is dependent on the ability of the pancreas to produce and store insulin. The mechanism is fundamentally constrained by the residual function of the pancreatic beta-cells and is functionally constrained if these cells are significantly depleted or non-functional.

Dosage and Administration Information

Solosa is administered via the oral route as a tablet. The administration involves a single daily dose that must be taken with breakfast or the first main meal of the day, establishing a relationship between dose timing and food intake.

The standard adult protocol begins with a low starting dose, typically 1 mg or 2 mg once daily. Subsequent dose adjustments are made in small increments of 1 mg or 2 mg, and the dose is not to be increased more frequently than every one to two weeks. The maximum recommended daily intake is 8 mg, although some protocols cite a maximum of 6 mg for standard use.

Use protocols require modification for certain patient groups. For older adults and patients with renal impairment, the starting dose is lower, at 1 mg once daily, with slow and cautious titration. The medication is not recommended for pediatric patients or in cases of severe hepatic dysfunction.

For proper administration, the tablets should be swallowed whole. If a scheduled dose is forgotten, the forgotten amount must not be corrected by increasing the next dose. Additionally, when co-administering with the medication Colesevelam, Solosa must be taken at least four hours prior to Colesevelam to prevent reduced absorption. The drug is generally intended for long-term maintenance therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Solosa (Glimepiride)


Evidence for Use as Single Therapy in Type 2 Diabetes

Research exploring Glimepiride's profile against key blood sugar markers in Type 2 Diabetes Mellitus (T2DM) was evaluated in randomized controlled trials (RCTs). These short-term studies were conducted in adults whose condition was not fully managed by lifestyle interventions alone. Research examined key outcomes related to systemic or functional imbalance, specifically monitoring changes in blood biomarkers such as Glycosylated Hemoglobin (HbA1c) and Fasting Plasma Glucose (FPG).

Studies report how symptoms evolved in the observed populations, and findings in the Glimepiride groups research reported measurable differences compared to the measurements reported in the groups receiving an inactive substance (placebo). This research provides insight into short-term changes and helps contextualize how patients reported their experience during the initial phase of treatment.


Evidence for Use in Combination Therapy

Glimepiride was also evaluated in add-on randomized controlled trials where adults with T2DM were not meeting their glycemic targets on an existing single-agent therapy. The goal of this research was to examine how outcomes reflecting functional measures—specifically shifts in blood glucose markers—evolved when Glimepiride was introduced alongside another drug.

Findings describe patterns observed in studies that included additional measurable shifts in the study's biomarkers when Glimepiride was added to an existing regimen. Research highlights changes measured during the study period, helping to contribute to the broader evidence landscape for combination approaches.


⏱️ Long-Term Studies and Durability of Effect

Evidence for Glimepiride also includes intermediate-term extension studies that explored the maintenance of observed glycemic shifts over periods of up to 2.5 years. Findings indicate that observed patterns of blood sugar management appeared to continue over these defined time intervals.

Special Study: Glimepiride Compared to Other Treatments

Long-term, large-scale studies, known as Cardiovascular Outcome Trials (CVOTs), were conducted in adults with T2DM. This research was not designed to show that Glimepiride is linked to a specific cardiovascular outcome, but rather to characterize its profile relative to newer agents. A major CVOT, which compared Glimepiride to a newer agent, explored the finding of noninferiority regarding the incidence of a composite outcome over the multi-year study duration. Study results reflect the specific conditions under which they were conducted.


‍‍‍ Evidence in Special Populations

Research has explored the use of Glimepiride in children and adolescents (typically ages 8 to 17) with T2DM. This research examined temporary physiological imbalance, specifically measuring changes in HbA1c over a short-term observation period. Studies reported how symptoms evolved in the observed populations, and data show patterns related to measured changes in HbA1c in this pediatric group.


What is Still Uncertain About Solosa Research

There is limited information for long-term outcomes that track event rates, such as major heart-related incidents, through dedicated, long-term Glimepiride trials compared to the standard of evidence for newer classes of diabetes medication. Additionally, data for certain groups remain insufficient, and the long-term effects of Glimepiride in children and adolescents are not fully established due to the short duration of the available trials.

Key Studies & References Efficacy and Safety of Glimepiride in Diabetes Mellitus: A Systematic Review

Frequently Asked Questions (FAQ)

Common questions about Solosa (FAQ)

Q: How quickly does Solosa start working after I take it?

A: According to official product information, after a single dose, the time required to reach the maximum blood-glucose-lowering effect is reported to be approximately 2 to 3 hours after administration. This information helps describe the drug's short-term activity in the body.

Q: How long do the effects of Solosa typically last?

A: Regulatory data indicates that the drug’s glucose-lowering effect is generally maintained over 24 hours with once-daily dosing. The medication is described in regulatory documents as a long-acting agent, and its mean dominant serum half-life is reported to be about 5 to 8 hours.

Q: Can Solosa be taken by older adults or seniors?

A: Official information states that Solosa can be used by older adults. However, caution is advised in this population due to a potentially increased risk of hypoglycemia, or low blood sugar. A lower starting dose and slow titration are often noted in the official guidance for older patients.

Q: What is the difference between Solosa and a similar drug, Xylos?

A: Solosa's active ingredient is classified as a sulfonylurea agent, which is a type of oral medicine used to lower blood sugar. Regulatory documents note that when switching from other oral antidiabetic agents, a healthcare provider must consider the properties of the previous medicine to manage the risk of low blood sugar.

Q: Can Solosa affect my mood or sleep?

A: While mood changes or sleep disturbance are not typically listed as primary side effects, regulatory documents note that hypoglycemia (low blood sugar) can cause certain symptoms. These potential signs of low blood sugar may include sleepiness, restlessness, disordered sleep, or feelings of aggressiveness.

Q: Can Solosa cause stomach upset or nausea?

A: Official documents list nausea as a common adverse drug reaction. Less frequent effects related to the digestive system, such as diarrhea and general pain, have also been noted in postmarketing reports.

Q: Is it true that Solosa is being studied for other conditions?

A: The medicine is officially indicated only for Type 2 Diabetes Mellitus. Regulatory documents specifically state the drug should not be used for treating Type 1 diabetes or diabetic ketoacidosis, and its use is established for this therapeutic indication.

Q: What kind of research evidence supports the use of Solosa?

A: Research supporting the use of the drug includes short-term randomized controlled trials (RCTs) in adults that examined outcomes like changes in key blood markers, such as Glycosylated Hemoglobin (HbA1c). Studies have also explored its effectiveness when used in combination therapy.

Q: Can Solosa affect my ability to drive or operate machinery?

A: Official guidance states that patients must be aware of the possibility of hypoglycemia (low blood sugar). Because low blood sugar can impair concentration, alertness, and reaction time, these effects may present a risk in situations like driving or operating complex machinery.

Q: Is Solosa considered a controlled substance?

A: Regulatory records from the FDA show that Solosa is not assigned a DEA schedule. It is categorized as a human prescription drug label with no official controlled substance classification.

Q: Does Solosa cause weight gain or weight loss?

A: Clinical trial data has explored weight changes in patients taking the drug over time. Findings have described a pattern involving a slight weight gain followed by gradual weight loss in some study groups monitored over the long term.

Q: Do I need to change my diet while I'm taking Solosa?

A: The drug is indicated for use as an adjunct to diet and exercise. Official documents note that the amount of the drug taken must be carefully balanced against the amount and type of food eaten, indicating that attention to a proper meal plan is part of the established therapeutic regimen.

Q: Are there any common foods I should avoid while taking Solosa?

A: There is no specific list of common foods generally restricted in regulatory documents. However, official guidance states that irregular mealtimes, skipped meals, or periods of fasting are factors that may lead to the occurrence of hypoglycemia (low blood sugar).

Q: Can Solosa make me sensitive to the sun?

A: Official patient information mentions that the drug may make skin more sensitive to sunlight. If this effect occurs, regulatory patient information describes protective measures, such as wearing appropriate clothing and using sunscreen.

Q: What is the purpose of the inactive ingredients in Solosa tablets?

A: Official drug descriptions list all ingredients, including the active ingredient and the inactive excipients (binders, fillers, colorants). These inactive substances are included to help form the tablet, maintain its stability over time, and facilitate the intended absorption and release of the active drug in the body.

Q: What should I do if a side effect of Solosa won't go away?

A: Patient guidance for non-serious side effects (such as mild dizziness or nausea) is to tell a healthcare professional if symptoms are severe or do not go away.

Q: Are there any specific laboratory tests needed when taking Solosa?

A: Dosage decisions are typically determined by the results of blood and urinary glucose determinations. Additionally, monitoring of HbA1c is a standard measure used to assess long-term glycemic control during the course of treatment.

Q: Is Solosa used to prevent a condition or to treat an active one?

A: Solosa is indicated as an adjunct to diet and exercise to improve glycemic control in adults with Type 2 Diabetes Mellitus. This indicates its use for treating an active, diagnosed condition and managing existing high blood sugar.

How should Solosa be stored and disposed of?

How to Store and Dispose of Solosa (Glimepiride)

The storage and disposal of Solosa tablets must strictly follow regulatory requirements to maintain product stability and safety.

Official Storage Requirements

Requirement Details
Temperature Store at Controlled Room Temperature: 20 C to 25 C (68 F to 77 F).
Protection Protect from light and moisture; do not freeze.
Container Keep in the original container and ensure it is tightly closed.
Safety Must be kept out of the reach of children.

Disposal Instructions

Expired or unused Solosa must be disposed of according to official guidelines. The preferred method is using a drug take-back program. If one is unavailable, dispose of the tablets in the household trash by mixing them with an undesirable substance, placing the mixture in a sealed bag, and discarding it. The medication is not recommended to be flushed down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Solosa found in:

A-Z Index: